Health Planning Commission: to ensure the shortage of drug supply to meet the basic drug needs of the masses.


Release time:

2016-03-14


Recently, the supply of life-saving drugs at low prices has been cut off from time to time, causing many patients to seek medicine everywhere. In the face of the "drug shortage" of low-priced drugs, the relevant person in charge of the Department of Drug Administration of the Health and Family Planning Commission told reporters on the 13th that the Health and Family Planning Commission will continue to take into account the needs of hospitals and grass-roots drugs, actively promote classified drug procurement, consolidate and improve the basic drug system, ensure the supply of drugs in shortage, and meet the basic drug needs of the masses.
In April 2014, the national health and Family Planning Commission and other relevant departments jointly formulated the opinions on ensuring the supply of commonly used low-cost drugs. In June of the same year, the "Notice on Doing a Good Job in the Procurement and Management of Commonly Used Low-cost Drugs" was issued, proposing to strengthen overall planning and coordination, and multi-pronged efforts to ensure the protection of commonly used low-cost drugs.
"The shortage of medicines is a global problem, and it is widespread in all countries in the world, including the United States." The above-mentioned person in charge said that the main reasons for the shortage of some drugs in China include: the seasonality of the supply of raw materials for drugs, the small amount of profits, and the shortage of production caused by the small number of raw materials or production enterprises; some places have been slow to implement online procurement, or still adopt various ways to intervene and limit the quotation of enterprises, which has affected the enthusiasm of enterprises in production and supply and caused policy shortage; the mechanism of supplementing medicine with medicine has not been completely broken, and the mechanism of information exchange and linkage response mechanism between departments has not yet been established.
Some people in the industry suggest that for rescue drugs and rare disease drugs that are clinically necessary, irreplaceable, uncertain in dosage, and not often produced by enterprises, a reserve system for such drugs should be established on a provincial or regional basis, and specialized agencies and special personnel should be responsible for the procurement, reserve and allocation of such drugs.
In this regard, the above-mentioned person in charge said that next, the Health and Family Planning Commission will work with relevant departments to implement the drug classification procurement policy and improve the drug shortage early warning and information disclosure mechanism. Taking provinces (autonomous regions and municipalities) as units, a number of hospitals and grass-roots medical and health institutions were selected as sentinels for monitoring drug shortages, and a drug shortage information reporting system was established. On the basis of the evaluation and summary of the pilot work of the fixed-point production of four first batch of essential drugs, such as Xedilan (rapid cardiotonic drug), the scope of fixed-point production of drugs was steadily expanded.
In addition, China's research and response measures to ensure the supply of drugs for rare diseases, that is, "orphan drugs", are still relatively backward, and there are no targeted and systematic incentive policies for the research and development, pricing, reimbursement and personnel training of drugs for rare diseases. Due to the small number of patients with rare diseases, small market capacity, high R & D and production costs, and low return on commercial investment, most rare diseases have no drugs available.
The above-mentioned person in charge responded that in December last year, the National Health and Family Planning Commission established a rare disease diagnosis and treatment and protection expert committee, which is responsible for researching and proposing the definition and scope of rare diseases in line with China's national conditions, and the prevention, screening, diagnosis and treatment of rare diseases. Suggestions on medication, rehabilitation and protection. Measures to safeguard the use of drugs for rare diseases will soon follow.